{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(2022)
Source:
NDA215866
(2022)
Source URL:
First approved in 2022
Source:
NDA215866
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761164
(2022)
Source URL:
First approved in 2022
Source:
BLA761164
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761261
(2022)
Source URL:
First approved in 2022
Source:
BLA761261
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761310
(2022)
Source URL:
First approved in 2022
Source:
BLA761310
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761148
(2022)
Source URL:
First approved in 2022
Source:
BLA761148
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761289
(2022)
Source URL:
First approved in 2022
Source:
BLA761289
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
NDA022231
(2022)
Source URL:
First approved in 2022
Source:
NDA022231
Source URL:
Class:
PROTEIN
Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.
Status:
US Approved Rx
(2022)
Source:
BLA761183
(2022)
Source URL:
First approved in 2022
Source:
BLA761183
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761238
(2022)
Source URL:
First approved in 2022
Source:
BLA761238
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
BLA761123
(2021)
Source URL:
First approved in 2021
Source:
BLA761123
Source URL:
Class:
PROTEIN
